medicina50巻6号

2013年06月発行

特集 最新の動脈硬化診療―どう診断し，どう治療するか？ 予防と治療の進め方

抗血小板薬

著者： 堀内久徳¹

所属機関： ¹東北大学加齢医学研究所

ページ範囲：P.1066 - P.1071

ポイント

◎血小板は速い流れのなかでも障害血管に相互作用することができるので，動脈血栓症発症に重要な役割を演ずる．

◎そのため，抗血小板薬はハイリスク症例の脳梗塞や心筋梗塞の予防に用いられる．

◎冠動脈ステント留置後一定期間はステント血栓症予防のため，アスピリンとADP受容体拮抗薬の2剤併用抗血小板療法が必須である．

◎抗血小板療法は，心血管イベントの予防効果とともに出血性合併症の増加は避けられず，功罪を考えて施行すべきである．

参考文献

1）Nakagawa Y, et al：Efficacy of Abciximab for Patients Undergoing Balloon Angioplasty. Circ J 73：145-151, 2009

2）Antithrombotic Trialists' Collaboration：Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324：71-86, 2002

3）Baigent C, et al：Aspirin in the primary and secondary prevention of vascular disease：collaborative meta-analysis of individual participant data from randomised trials. Lancet 373：1849-1860, 2009

4）Ogawa H, et al：Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 Diabetes. JAMA 300：2134-2141, 2008

5）Toyoda K, et al：Dual Antithrombotic Therapy Increases Severe Bleeding Events in Patients With Stroke and Cardiovascular Disease. Stroke 39：1740-1745, 2008

6）Yamane K, et al：Impact of platelet reactivity on long-term clinical outcomes and bleeding events in Japanese patients receiving antiplatelet therapy with aspirin. J Atheroscler Thromb 19：1142-1153, 2012

7）CAPRIE Steering Committee：A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events（CAPRIE）. CAPRIE Steering Committee. Lancet 348：1329-1339, 1996

8）Diener HC, et al：Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients（MATCH）：randomised, double-blind, placebo-controlled trial. Lancet 364：331-337, 2004

9）Bhatt DL, et al：Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354：1706-1717, 2006

10）Bhatt DL, et al：Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 49：1982-1988, 2007

11）Kimura T, et al：Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation：five-year outcome of the j-Cypher Registry. Circulation 125：584-591, 2012

12）Jinnai T, et al：Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan. Circ J 73：1498-1503, 200913）Mega JL, et al：Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360：354-362, 2009

13）Mega JL, et al：Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360：354-362, 2009

14）Abraham NS, et al：ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines：a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use：a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation 122：2619-2633, 2010

15）Gilard M, et al：Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin：the randomized, double-blind OCLA（Omeprazole CLopidogrel Aspirin）study. J Am Coll Cardiol 51：256-260, 2008

16）Yamane K, et al：Effects of PPIs and an H2 blocker on the antiplatelet function of clopidogrel in Japanese patients under dual antiplatelet therapy. J Atheroscler Thromb 19：559-569, 2012

17）Bhatt DL, et al：Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 363：1909-1917, 2010

18）Gotoh F, et al：Cilostazol stroke prevention study：A placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 9：147-157, 2000

19）Shinohara Y, et al：Cilostazol for prevention of secondary stroke（CSPS 2）：an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 9：959-968, 2010